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Familial incontinentia pigmenti (IP [MIM 308310]), or Bloch-Sulzberger syndrome, is an X-linked dominant and
male-lethal disorder. We recently demonstrated that mutations in NEMO (IKK-g), which encodes a critical com-
ponent of the NF-kB signaling pathway, were responsible for IP. Virtually all mutations eliminate the production
of NEMO, causing the typical skewing of X inactivation in female individuals and lethality in male individuals,
possibly through enhanced sensitivity to apoptosis. Most mutations also give rise to classic signs of IP, but, in this
report, we describe two mutations in families with atypical phenotypes. Remarkably, each family included a male
individual with unusual signs, including postnatal survival and either immune dysfunction or hematopoietic dis-
turbance. We found two duplication mutations in these families, at a cytosine tract in exon 10 of NEMO, both of
which remove the zinc (Zn) finger at the C-terminus of the protein. Two deletion mutations were also identified
in the same tract in additional families. However, only the duplication mutations allowed male individuals to
survive, and affected female individuals with duplication mutations demonstrated random or slight skewing of X
inactivation. Similarly, NF-kB activation was diminished in the presence of duplicationmutations andwas completely
absent in cells with deletion mutations. These results strongly indicate that male individuals can also suffer from
IP caused by NEMO mutations, and we therefore urge a reevaluation of the diagnostic criteria.
Familial incontinentia pigmenti (IP [MIM 308310]), or
Bloch-Sulzberger syndrome, is a rare genodermatosis
that segregates as an X-linked dominant trait with pre-
natal male lethality (Landy and Donnai 1993). The hall-
mark sign of IP is the presence of skin lesions in affected
female newborns. These lesions progress through vari-
ous stages and result in hypopigmented patches along
lines of X inactivation (Spitz 1996, pp. 66–67). The
name of the disorder derives from the observation of
incontinence of melanin from the epidermis into the der-
mis. The most significant medical problem in IP is blind-
ness due to hypervascularization and consequent retinal
detachment. Other manifestations include alopecia, hy-
podontia or anodontia, eosinophilia, nail dystrophy, and
neurological complications. These medical problems, to-
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gether with the skin-pigmentation abnormality, consti-
tute the typical IP phenotype. The IP gene is thought to
be essential for viability, since affected hemizygous male
individuals die in utero and female patients survive with
the mutant X chromosome selectively inactivated (Par-
rish et al. 1996; Woffendin et al. 1999). On the basis
of these characteristics, we screened a gene called
“NEMO” and identified mutations in multiple IP pa-
tients (International IP Consortium 2000).
NEMO (IKK-g) encodes a regulatory subunit of the
IKK complex, which is central to activation of the NF-
kB pathway (DiDonato et al. 1997; Israel 2000). NF-kB
is sequestered in the cytoplasm by IkB inhibitory pro-
teins, but, on stimulation by cytokines, IKK phospho-
rylates IkB and targets it for ubiquitin-mediated degra-
dation. Release from IkB allows NF-kB to translocate
into the nucleus and activate transcription of target
genes. Knockout models for NF-kB subunits or com-
ponents of the signaling cascade have shown that NF-
kB is responsible for preventing apoptosis, particularly
in response to TNF-a (Barkett and Gilmore 1999; Ger-
ondakis et al. 1999). Hence, loss of NEMO in cells of
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Table 1
Exon-10 Cytosine Tract Mutations, Corresponding Phenotypes, X-Inactivation Status, and NEMO Activity
Family
Phenotype
in Female
Subjects Phenotype in Male Subjects Mutation
Predicted
Amino Acids
X-Inactivation
Status
Average NEMO Activity
Relative to Wild Typea
XL213 Typicalb 1 spontaneous abortion DC1161 P389fsX60c Skewed 10% p background
XL267 Typical No male subjects in pedigree dupC1161 P389fsX4 Random 34%
XL287 Typical 1 spontaneous abortion DC1161 P389fsX60c Skewed 10% p background
XL320 Typicald Death after 1 d, from hemorrhaging dup1166-78 P393fsX4 Slight skewing 19%
XL344 Typical Immune dysfunction; skinb; teethb dupC1161 P389fsX4 Random 34%
XL345 Typical No male subjects in pedigree DC1161 P389fsX60c Skewed 10% p background
XL374 Typical 3 spontaneous abortions D1163-75 S387fsX58e Skewed Not done
a By genetic complementation assay in a NEMO-mutant cell line. All values relative to wild type (100%).
b Typical of IP—skin pigmentation, conical teeth, retinal detachment, alopecia, CNS problems. Not all signs demonstrated in families.
c 60 novel amino acids: RSHLTSAVPSASIRPLIWTPCRYMSWSALSRAGQCKATACRGRARDRAVCAFLSRLPSPGX.
d Female family members show variation in expression of phenotype.
e 58 novel amino acids: HLTSAVPSASIRPLIWTPCRYMSWSALSRAGQCKATACRGRARDRAVCAFLSRLPSPGX.
IP patients most likely results in apoptosis, which can
explain both the male lethality and the skewing of X
inactivation in female individuals. The C-terminus of
NEMO is indispensable to activate NF-kB downstream,
although the exact residues necessary for this function
have yet to be determined (Rothwarf et al. 1998; Ya-
maoka et al. 1998).
Most cases (∼85%) of IP are due to a recurrent de-
letion within NEMO that removes exons 4–10 (Inter-
national IP Consortium 2000). All reported mutations,
including the rearrangement type, cause typical IP. How-
ever, while its penetrance approaches 100%, this dis-
order shows variable expressivity, even within the same
family. To add to this complexity, although IP has tra-
ditionally been classified as a male-lethal disorder, a
few cases have been reported in male patients (Kirchman
et al. 1995; Scheuerle 1998). The first NEMO mutation
was recently found in a surviving male patient with ab-
normalities of the skin, teeth, and eyes, but also with
osteopetrosis and immune dysfunction (International IP
Consortium 2000). This patient died of tuberculosis at
age 2.5 years. We have characterized two additional
male cases, to test the hypothesis that male IP patients
survive due to milder (hypomorphic) mutations. Anal-
ysis of these two families now reveals the genetic basis
for the occurrence of IP in male individuals.
Family XL320 was described elsewhere (Roberts et al.
1998), but the diagnosis of IP was complicated by sub-
stantial phenotypic variation among the affected female
family members. A male infant (XL320-04), who had
been carried to term, died from severe hemorrhage 24
h after birth (table 1). Prenatal testing by linkage anal-
ysis, using nearby informative markers, in a subsequent
pregnancy, predicted another affected male fetus
(XL320-09). This pregnancy was terminated, and the
mother (XL320-01) experienced severe bleeding during
the procedure, further suggesting that the mutation in
this family disrupted hemostasis. A second family,
XL344, also included female members with typical signs
of IP (table 1). An affected male individual (XL344-04)
exhibited skin pigmentation and dental problems but
also demonstrated immune dysfunction. He suffered
multiple episodes of infection, including meningitis and
pneumonia, due to poor lymphocyte function and re-
markably low levels of circulating IgG. He also exhibited
heat intolerance with hyperthermia, anhidrosis, eczema,
and fine sparse hair, which led to a diagnosis of ecto-
dermal dysplasia (ED) (X-linked anhidrotic ectodermal
dysplasia [MIM 305100], autosomal recessive hypo-
hidrotic ectodermal dysplasia [MIM 224900], and au-
tosomal dominant hidrotic ectodermal dysplasia [MIM
129500]). Now, at age 3 years, he receives routine sup-
plements of IgG, to prevent recurrent infections. He is
currently losing weight, complains of abdominal pains,
and tests positive for hepatosplenomegaly. He has also
contracted mycobacterium avium intracellulare, an in-
fection common among patients with AIDS.
DNA samples from these two families (XL320 and
XL344) were examined for all coding exons of NEMO
by conformation-sensitive gel electrophoresis (CSGE)
(Ganguly et al. 1993). PCR products from exon 10 dem-
onstrated altered band sizes in both families (fig. 1a).
Sequencing of exon-10 PCR products from XL320-
01 and XL320-04 revealed a 13-base duplication
(dup1166-78) (fig. 1b and 1c) at the end of a cytosine
tract (the “C7 tract”). This duplication would cause
frameshift after amino acid P393 and protein truncation
after addition of four novel amino acids (fig. 1d and
table 1). Sequence analysis of all NEMO exons in af-
fected male subject XL320-04, including the noncoding
exon 1, failed to identify other base changes. Exon-10
PCR products from family XL344 (fig. 1a) contained a
duplication of one cytosine (dupC1161), also within the
C7 tract (fig. 1b). A frameshift after amino acid P389
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Figure 1 Mutation analysis of NEMO exon 10. A, CSGE bandshifts in affected members. B, Sequence analysis reveals mixed sequence
(arrows indicate start point) due to mutations. C, DNA-sequence alignments between normal and mutant exon-10 sequences, with the cytosine
tract at the left. Arrows point to mutations, and blue boxes mark the duplications. D, Protein-sequence alignments show the addition of novel
amino acids, enclosed in blue boxes. Orange boxes indicate stop codon positions.E,Mutational mechanism at the cytosine tract, with duplications
(1, 3) on top and deletions (2, 4) at the bottom.
causes addition of the same four novel amino acids as
are found in the XL320 mutant protein (fig. 1c). Despite
the addition of identical novel amino acids, the phe-
notypes of the male subjects in these two families were
entirely different (table 1). One additional family
(XL267) demonstrated the same base duplication,
dupC1161, as in family XL344, but no male offspring
have been reported in this pedigree (table 1). The shorter
protein sizes predicted from these mutations were dem-
onstrated by in vitro translation experiments (fig. 2b).
Given the nature of the mutations in families XL320
and XL344, we expected that reciprocal mutations—
namely, a 13-base deletion and a single-cytosine dele-
tion—might also be found. A 13-base deletion (D1163-
75) at the C7 tract was identified in family XL374 (fig.
1a–c). However, this mutation was not the precise re-
ciprocal of the XL320 mutation but was shifted 5’ by
two bases. This mutation predicts a frameshift after
amino acid S387 and protein truncation after addition
of 58 novel amino acids to the C-terminus of the protein
(fig. 1d and table 1). Three additional families exhibited
a deletion of a single cytosine (DC1161) within the C7
tract (fig. 1a–c and table 1), which is also expected to
cause a frameshift at amino acid P389 and protein trun-
cation after addition of 60 novel amino acids (fig. 1d
and table 1). This larger protein size, caused by DC1161,
was demonstrated by in vitro translation experiments
(fig. 2b). Notably, after the first two residues, both de-
letion mutations add the same novel amino acid se-
quence to the truncated protein.
We analyzed all available family members for the du-
plication and deletion mutations, and altered band sizes
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Figure 2 Analysis of NEMO activity by means of a genetic com-
plementation assay in a NEMO-minus cell line. A, Expression analyses
with various NEMO cDNA constructs were performed in six trials;
the average luciferase-expression values are shown. Specific mutations
introduced into the NEMO cDNA are indicated below the chart. The
DC1161 deletion shows complete absence of complementation activity
(same as background). In contrast, the duplication mutations,
dupC1161 and dup1166-78, show diminished and residual activities.
B, In vitro translation experiment confirms both the expected smaller
protein sizes due to the duplication mutations and a larger protein size
with the DC1161 mutation.
Figure 3 X-inactivation analysis in pedigrees with exon-10 mu-
tations. The methylation-based assay detects the active X chromosome
after digestion with a methylation-sensitive enzyme, HpaII (H). Two
bands in the “H” lanes indicate random X inactivation, and a single
band suggests complete skewing of X inactivation. The RsaI (R) digest
serves as control, and both alleles are amplified. A, Affected members
with the DC1161 mutation show complete skewing of X inactivation.
B, Patients with the dupC1161 mutation show random X inactivation.
C, Affected female subjects with the dup1166-78 mutation in family
XL320 show mild skewing (∼60%) of X inactivation. D, Family
XL374 has the D1163-75 mutation, which causes complete skewing
in affected members.
were detected exclusively in affected members (fig. 1a).
Moreover, CSGE analysis of 50 normal female subjects
(100 X chromosomes) failed to reveal variations, con-
firming that the base alterations we found were not com-
mon polymorphisms (data not shown). During prepa-
ration of this report, another group reported that the
mutation in family XL320 was a deletion that removes
the first exon (Makris et al. 2000). We have analyzed
the entire NEMO gene in XL320 and have found a
mutation in exon 10, with complete preservation of exon
1, as described above. Southern blot analysis also failed
to identify aberrant bands indicative of potential ge-
nomic rearrangements within NEMO.
We hypothesized that some male individuals survive
because their mutations are “milder” (hypomorphic)
and not cell lethal. Thus, we expected female individuals
with the same mutations to show random or only min-
imal skewing of X inactivation, rather than the complete
skewing observed in female patients with classic IP (Par-
rish et al. 1996). We examined the X-inactivation status
in families with the duplication mutations by means of
a method established elsewhere, based on digesting ge-
nomic DNA with a methylation-sensitive enzyme,HpaII,
and amplifying a polymorphism at the HUMARA locus
(Allen et al. 1992; Parrish et al. 1996). In support of
our hypothesis, blood leukocytes from female subjects
carrying either the dup1166-78 or dupC1161 mutations
showed slight skewing or random X inactivation, re-
spectively (fig. 3b and 3c). Hence, these NEMO muta-
tions were apparently not deleterious enough to cause
lethality in cells with an active mutant X chromosome
and are consistent with the survival to term of affected
male individuals in these families. In contrast with family
XL344, the slight skewing in family XL320 could ac-
count for the more-severe phenotype in the XL320-04
male patient. We also examined the X-inactivation status
in families with the deletion mutations (D1163–75 and
D1161) and showed that they result in complete skewing
of X inactivation (fig. 3a and 3d). Hence, the deletion
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mutations appear to be cell lethal, similar to other IP
mutations (International IP Consortium 2000). More-
over, all families with deletion mutations, except XL345,
have reported spontaneous abortions, presumably
caused by in utero demise of affected male fetuses (table
1).
NEMO is central to activation of the NF-kB pathway,
and its absence completely abolishes this signaling path-
way (Yamaoka et al. 1998; International IP Consortium
2000; Makris et al. 2000; Schmidt-Supprian et al. 2000).
Therefore, concordant with X inactivation, we expect-
ed hypomorphic mutations to cause reduction, rather
than elimination, of NF-kB activation. The dupC1161,
dup1166-78, and DC1161 mutations were engineered
into an expression vector and, to evaluate their genetic
complementation ability by a method described else-
where, were transiently transfected into NEMO-minus
cells (Courtois et al. 1997; Yamaoka et al. 1998; Inter-
national IP Consortium 2000). The mutant cDNA con-
structs introduced into these cells produce NEMO pro-
teins that activate NF-kB in varying degrees, depending
on the mutations they contain. NF-kB then activates a
reporter gene (luciferase) by binding target sites in the
promoter, and, hence, luciferase levels reflect NEMO ac-
tivity and NF-kB activation. In support of the X inac-
tivation and phenotypic data, the deletion mutation
completely failed to complement NEMO activity in these
cells (fig. 2a). The duplication mutations resulted in re-
sidual (19.5%, with XL320 mutation) or reduced (34%,
with XL344 mutation) activity relative to wild type (fig.
2a). The greater reduction in XL320 may explain the
postnatal lethality of the male subject (XL344-04) car-
rying this mutation, although the 34% activity in XL344
is apparently sufficient for survival past infancy. These
experiments measured activity in vitro, but these mu-
tations may be of a different nature in vivo, with effects
on protein structure and stability. Analysis of fibroblast
cells from patients would have been useful to validate
these results, but the death of the first male subject and
difficult access to the second male subject prevented in-
vestigations in vivo.
Although IP has been considered a male-lethal disease,
this report now describes mutations in male patients that
demonstrate atypical forms of IP. However, it is imper-
ative to understand that affected female relatives of these
male individuals exhibited classic IP signs. Another
group recently reported mutations in male individuals
diagnosed with ectodermal dysplasia and immune dys-
function (Zonana et al. 2000). Although these families
were described as having a novel syndrome in the form
of ED and ID, it is likely that they are simply variants
of IP, since they present clinical features associated with
IP such as abnormal dentition, skin pigmentation ab-
normalities, and alopecia. The proband from the fourth
pedigree (HED-ID 4), in this report, resembled the
XL344 family described here. However, although the
carrier female in family HED-ID 4 did not suffer from
any medical problems, affected female individuals in
family XL344 demonstrated typical IP skin-pigmenta-
tion and retinal abnormalities, a contrast that could be
explained by variation in expression due to differences
in X inactivation between the affected female individuals
of these two families. Similarly, while the XL320 phe-
notype appears to be a novel disorder of IP combined
with disrupted hemostasis, this should also be consid-
ered a variation of IP in male individuals. These variant
phenotypes arise because of the full expression of mu-
tations in male indiviuals, whereas the X inactivation in
carrier female individuals prevents the complete phe-
notypic manifestation of the mutations, resulting in typ-
ical IP.
These data provide a basis for understanding the func-
tion of the NEMO protein, especially the C-terminus,
which is indispensable for function (Rothwarf et al.
1998; Yamaoka et al. 1998). We have suggested else-
where that removal of a Zn finger at the C-terminus is
lethal, since nearly all mutations initially identified re-
moved this domain (International IP Consortium 2000).
In support of this interpretation, we have elsewhere de-
scribed a male patient with IP with a stop codon mu-
tation that resulted in the addition of 21 novel amino
acids to the C-terminus, but this mutation preserved the
Zn finger and allowed this patient to survive beyond
birth (International IP Consortium 2000). However, al-
though all the mutations reported here lead to removal
of the Zn finger, only the deletion mutations were lethal
in the embryonic period. Thus, male individuals may
survive in spite of mutations that remove the Zn finger,
indicating that the region within the C-terminus of
NEMO that is indispensable for function must lie be-
yond the Zn finger domain. The specific role of the Zn
finger is not known, and these mutations should be help-
ful in the determination of its function.
With knowledge of NEMO’s role in the NF-kB path-
way, how can we explain the unusual phenotypes ob-
served in male subjects from families XL320 and
XL344? A few reports have associated IP with immune
problems (Dahl et al. 1975; Jessen et al. 1978; Ment et
al. 1978; Person 1985; Menni et al. 1990), and knock-
out-mouse models for NEMO suggest that immune dys-
function in IP results from uncontrolled apoptosis in the
thymus and spleen (Makris et al. 2000). The phenotype
of the male individual with the stop codon mutation was
attributed to the addition of the novel amino acids to
the end of the NEMO protein (International IP Con-
sortium 2000). This may affect the stability of the pro-
tein or may mask the nearby leucine zipper domain,
which is essential for dimerization. The immune dys-
function in this male subject, as well as in the XL344
male subject, may arise from cellular apoptosis in tissues
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critical to the immune system, including the thymus and
spleen. Similarly, the XL320 mutation may affect he-
matopoietic or vascular development due to a deleteri-
ous effect on tissues involved in these processes. Vascular
development is also thought to be the basis for the most
significant medical problems in IP—namely, blindness
caused by retinal detachment and mental retardation due
to central nervous system malformations (Goldberg and
Custis 1993; Francis and Sybert 1997). In this regard,
a recent report demonstrated that primary congenital
lymphedema (MIM 153100) results from mutations in
vascular endothelial growth-factor receptor 3 (VEGFR-
3), which implements its effects via the NF-kB pathway
(Karkkainen et al. 2000). Knockout models forVEGFR-
3 demonstrate absence of a primary vascular network
and embryonic lethality (Dumont et al. 1998). There-
fore, the vascular anomalies in IP may be due to dis-
ruption, via NEMO, of the signaling between VEGFR-
3 and NF-kB.
Since IP has always been considered a male-lethal dis-
ease, it is likely that numerous cases of IP in male patients
have been misdiagnosed with other human disorders.
Our data clearly demonstrate that male individuals can
suffer from IP. This observation has implications for clin-
ical care, genetic counseling, and prenatal diagnosis. In
the past, linkage analysis was the only method for pre-
natal diagnosis, but with knowledge of the involvement
of NEMO, prenatal DNA samples can now be quickly
subjected to molecular analysis. Because of the formerly
held belief that affected male individuals undergo spon-
taneous abortion, some families currently continue a
pregnancy when a male fetus has inherited the mutant
haplotype. Therefore, if male patients do not have the
common rearrangement mutation, it is imperative to rule
out exon-10 mutations, because a devastating phenotype
is still possible. In this regard, we emphasize that IP male
individuals may present additional complications not
seen in classic IP, such as immune dysfunction or hem-
orrhaging. Such variant phenotypes often cause misdi-
agnosis in any disease, as illustrated by an original di-
agnosis of ectodermal dysplasia in family XL344. The
genes responsible for X-linked and autosomal ecto-
dermal dysplasia have been discovered, and they pro-
duce proteins similar to TNF and its receptor, TNFR
(Kere et al. 1996; Monreal et al. 1999). These proteins
activate NF-kB through NEMO (Kumar et al. 2000) and
will be useful in understanding the skin-pigmentation
and hair abnormalities that are common to both ED and
IP. However, since IP has been associated with immune
deficiency but ED has not, and because the XL344-04
male subject was initially diagnosed with ED, we had
predicted that, in cases of apparently variant forms of
ED with immune deficiency, mutations in NEMO would
be present. Indeed, this was demonstrated recently by
another group (Zonana et al. 2000). Similarly, variant
phenotypes of Partington syndrome II (MIM 301220)
and Goltz syndrome (MIM 305600), especially if they
occur sporadically, and unexplained cases of skin ab-
normalities with immunodeficiency (Ment et al. 1978;
Ruiz-Maldonado and Orozco-Covarrubias 1997) are
good candidates to examine for NEMO mutations.
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